文献速递头颈部肿瘤放疗

头颈部放化疗急性毒性评估的观察者间一致性:对临床试验终点选择的意义

Interobserver Agreement in Acute Toxicity Assessment During Head and Neck Radiation Therapy/Chemoradiation Therapy: Implications for Endpoint Selection in Clinical Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-08-01

结果显示,患者层面最大毒性(≥2级和≥3级)的观察者间一致性为一般至中等,口腔黏膜炎差异最大;每周评估的一致性更高。

要点

  • 最大急性毒性作为终点时,各域观察者间一致性仅为一般至中等。
  • 口腔黏膜炎不一致性最大,即使同一中心观察者间也明显。
  • 每周评估的一致性高于最大毒性,可作为补充终点。

核心结论

  • 头颈部放化疗最大急性毒性的观察者间一致性为一般至中等,口腔黏膜炎不一致性最大。
  • 最大毒性仍是实用且广泛使用的终点,但解读需谨慎。
  • 每周评估可能提供更可重复的补充终点,尤其适用于跨试验比较。

研究设计与样本

  • 由2名独立、盲法放射肿瘤科医生每周使用CTCAE v5.0评估急性毒性。
  • 评估皮炎、口腔黏膜炎、吞咽困难和口干四个域,主要终点为患者层面最大毒性(二分为≥2级和≥3级),一致性用Cohen's κ评估。

主要发现

  • 最大≥2级毒性发生率(观察者1 vs 观察者2):皮炎55.4% vs 45.9%,口腔黏膜炎91.9% vs 70.3%,吞咽困难95.9% vs 91.9%,口干55.4% vs 58.1%。
  • 最大≥2级毒性的κ值:皮炎0.33、口腔黏膜炎0.35、吞咽困难0.41、口干0.23(一般至中等)。
  • 最大≥3级毒性的κ值:皮炎0.79、口腔黏膜炎0.41、吞咽困难0.63、口干0.25。
  • 每周评估≥2级毒性的汇总一致性更高(κ=0.49-0.89),第5至6周一致率最高。

关键数值与推荐

  • 最大≥2级毒性κ值范围为0.23-0.41,最大≥3级毒性κ值范围为0.25-0.79。
  • 每周评估≥2级毒性汇总κ值为0.49-0.89。

临床怎么用

  • 解读头颈部放化疗试验中最大急性毒性终点时需考虑观察者间不一致性。
  • 可考虑将每周毒性评估作为补充终点以提高可重复性。
  • 口腔黏膜炎和口干等一致性较低的毒性域需更标准化评估。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Acute toxicity is a key endpoint in head and neck radiation therapy (RT) and chemoradiation therapy (CRT) trials and is most commonly reported as maximum toxicity per patient. However, the reproducibility of clinician-reported toxicity grading remains incompletely characterized. We evaluated interobserver agreement in acute toxicity assessment, focusing on maximum toxicity as the primary endpoint. METHODS AND MATERIALS: This predefined subgroup analysis was conducted in a prospective randomized controlled trial of patients with head and neck squamous cell carcinoma undergoing curative-intent RT/CRT. Acute toxicities were assessed weekly using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 by 2 independent, blinded radiation oncologists. Four domains were evaluated: dermatitis, oral mucositis, dysphagia, and xerostomia. The primary endpoint was patient-level maximum toxicity, dichotomized as grade ≥2 and grade ≥3. Interobserver agreement was assessed using Cohen's κ. RESULTS: Seventy-four patients were included. For maximum grade ≥2 toxicity, the incidence (observer 1 vs observer 2) was 55.4% vs 45.9% for dermatitis, 91.9% vs 70.3% for mucositis, 95.9% vs 91.9% for dysphagia, and 55.4% vs 58.1% xerostomia, with κ values of 0.33, 0.35, 0.41, and 0.23, respectively (fair to moderate). For grade ≥3 toxicity, κ values were 0.79 for dermatitis, 0.41 for mucositis, 0.63 for dysphagia, and 0.25 for xerostomia. Pooled weekly agreement for grade ≥2 toxicity was higher (κ = 0.49-0.89), with peak concordance during weeks 5 to 6. CONCLUSIONS: Interobserver agreement for maximum acute toxicity was fair to moderate across domains of head and neck RT/CRT, with the largest discordance for oral mucositis, even between observers at the same center. Although maximum toxicity remains a pragmatic and widely used endpoint, caution is warranted in its interpretation, and weekly assessment may offer a more reproducible complementary endpoint, particularly for cross-trial comparisons.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sinha S, Kumar A, Mohanty S, et al. Interobserver Agreement in Acute Toxicity Assessment During Head and Neck Radiation Therapy/Chemoradiation Therapy: Implications for Endpoint Selection in Clinical Trials. Int J Radiat Oncol Biol Phys. 2026. PMID: 42542300. doi:10.1016/j.ijrobp.2026.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。